L4I Logo
  • Emerging Infections
  • THEMES
  • USAID INVESTMENTS
  • SPECIAL FOCUS AREAS
    • Corporate TB Pledge
    • Urban Health
    • GESI
  • LEARNING LIBRARY
  • Primary Healthcare

This section hosts guidelines, manuals and toolkits to strengthen public health practice.

Resources

FILTER
BY CATEGORY

View All

COVID-19 Stay Tuned Nutrition For implementers For policymakers Report For researchers Research Urban Health M&E
Emerging Pandemics

Cardiovascular Disease and Use of Renin‑Angiotensin System Inhibitors in COVID‑19

23 May 2022

The safety of renin-angiotensin system (RAS) inhibitors in COVID-19 is still being debated. A probable link between cardiovascular disease (CVD) and COVID-19 has recently been discovered in investigations. This article seeks to summarize the evidence on the use of RAS inhibitors in COVID-19-positive CVD patients, with an emphasis on RAS inhibitor safety and its link to COVID-19. RAS inhibitors may be indicated for chronic heart failure or chronic renal disease, in which case self-discontinuation of these medicines without first consulting a physician could result in disintegration within days to weeks, severely reducing cardiopulmonary reserve in COVID-19 patients. Other antihypertensive medications for these illnesses may not be able to replicate the benefits of ACE inhibitors/ARBs. While no data on the effect of temporarily stopping RAS medications on mortality in COVID-19 patients has been revealed, information extrapolated from other patient scenarios suggests harm.

Download PDF
PUBLISHED BY
American Journal of Cardiovascular Drugs
YEAR OF PUBLISHING
2020
AUTHORS
Chia Siang Kow, et al.

Categories

COVID-19
KEY ORGANIZATIONS

FOLLOW US

  • HOME
  • THEMES
  • USAID INVESTMENTS
  • SPECIAL FOCUS AREAS
  • LEARNING LIBRARY
  • ABOUT US
  • CONTACT US
  • PRIVACY POLICY
Disclaimer: This website is made possible by the support of the American People through the United States Agency for International Development (USAID). The Learning4impact partnership is supported by USAID/India Health Office, under Cooperative Agreement # 72038618CA00001 with Swasti. The information provided on this website is not official U.S. Government information and does not necessarily represent the views or positions of USAID, the United States Government, or Swasti.
Copyright 2023 Swasti Health Catalyst

Get the latest!

Learning4impact provides a wealth of resources to support your public health work or research.

Sign up to get latest resources on public health!

Submit Feedback

Download Now

Yes, Subscribe me to the Learning4impact newsletter!
  • EMERGING INFECTIONS
  • THEMES
  • USAID INVESTMENTS
  • SPECIAL FOCUS AREAS
    • Corporate TB Pledge
    • Urban Health
    • Inclusive Development
  • LEARNING LIBRARY
  • Primary Healthcare